Seres Therapeutics, Inc. is a microbiome therapeutics company focused on developing novel biological drugs to modulate the microbiome and restore health by repairing the function of a disrupted microbiome to a non-disease state.

Seres Therapeutics, Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

COM:SERESTHERAPEUTICS

Seres Therapeutics, Inc.

Last Close

0.82

13/02 19:15

Market Cap

139.65M

Beta: -

Volume Today

274.40K

Avg: -

name

homepage url

country

crunchbase url

employee count

sector

industry

revenue

Description

peer of

competitor of

Metrics